Christel Menet, PhD

Chief Scientific officer
Confo Therapeutics
zwijnaarde, Belgium

Disclosure information not submitted.

Presentation(s):

• MON-612 - CFTX-2034: A First‑In‑Class SSTR5‑Selective Agonist Antibody for the Treatment of Post‑Bariatric Hypoglycemia

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT